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A B S T R A C T
Background: Perinatally-acquired HIV infection commonly causes stunting in children; how this aﬀects bone and
muscle development is unclear. We investigated diﬀerences in bone and muscle mass and muscle function be-
tween children with HIV (CWH) and uninfected children.
Setting: Cross-sectional study of CWH (6–16 years) receiving antiretroviral therapy (ART) for> 6months and
similar aged children testing HIV-negative at primary health clinics in Zimbabwe.
Methods: From Dual-energy X-ray Absorptiometry (DXA) we calculated total-body less-head (TBLH) Bone
Mineral Content (BMC) for lean mass adjusted-for-height (TBLH-BMCLBM) Z-scores, and lumbar spine (LS) Bone
Mineral Apparent Density (BMAD) Z-scores.
Results: The 97 CWH were older (mean age 12.7 vs. 10.0 years) and taller (mean height 142 cm vs. 134 cm) than
77 uninfected. However, stunting (height-for-age Z-score≤−2) was more prevalent in CWH (35% vs. 5%,
p < 0.001). Among CWH, 15% had low LS-BMAD (Z-score≤−2) and 13% low TBLH-BMCLBM, vs. 1% and 3%
respectively in those uninfected (both p≤ 0.02). After age, sex, height and puberty adjustment, LS-BMAD was
0.33 SDs (95%CI -0.01, 0.67; p=0.06) lower in CWH, with no diﬀerences by HIV status in TBLH-BMCLBM, lean
mass (0.11 [−0.03, 0.24], p=0.11) or grip strength (0.05 [−0.16, 0.27], p=0.62). However, age at ART
initiation was correlated with both LS-BMAD Z-score (r=−0.33, p=0.001) and TBLH-BMCLBM Z-score
(r=−0.23, p=0.027); for each year ART initiation was delayed a 0.13 SD reduction in LS-BMAD was seen.
Conclusion: Size-adjusted low bone density is common in CWH. Delay in initiating ART adversely aﬀects bone
density. Findings support immediate ART initiation at HIV diagnosis.
1. Introduction
In 2017, globally, up to 1.8 million children were living with HIV
[1], 90% in sub-Saharan Africa where HIV remains the leading cause of
death [2]. The scale-up of antiretroviral therapy (ART) has dramatically
improved survival for children living with HIV [3]; changing the in-
fection from one that was almost invariably fatal to a chronic treatable,
but incurable, condition. However, even in the era of ART, children
experience a range of multisystem morbidities due to their infection
and/or their treatment [4].
Growth failure, e.g. stunting (poor linear growth), is one of the most
common manifestations of perinatally-acquired HIV infection, aﬀecting
up to 50% of children [5]. However, the impact on bone development
in children is not well understood. A recent systematic review of bone
health identiﬁed a high prevalence of low bone mass (when bone mass
is two or more standard deviations [SD] below that expected for age) in
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children and adolescents living with HIV in high income countries
(HICs), but found no studies from low income countries (LICs) [6].
Importantly, a one SD reduction in bone mass is associated with a
doubling in childhood fracture risk, in otherwise healthy children [7].
In addition, adolescence is a crucial period of bone mass accrual, with
peak bone mass (PBM) achieved at the end of skeletal maturation. Low
PBM is a critical determinant of subsequent adult osteoporotic fracture
risk [8]; a 10% reduction in PBM doubles fracture risk in adulthood
[9,10].
Muscle strength and bone strength are closely related; muscles exert
forces on bone resulting in bone adaptation in size and strength [11].
HIV infection and consequent ill-health may result in reduced physical
activity, which in turn may impair muscle strength and skeletal impact
loading, impairing bone development [12–14]. Furthermore, ART may
itself adversely aﬀect bone and muscle health [15,16]. Few studies have
compared muscle strength and function between HIV infected and un-
infected children [13]. If greater muscle strength predicts higher bone
mass, then physical activity interventions could potentially optimise
musculoskeletal health.
The aim of this study was to determine the prevalence of low bone
density among children with HIV (CWH) in Zimbabwe, and factors
associated with low bone density, after accounting for body size. We
further aimed to establish whether lean muscle mass and function are
lower among CWH than uninfected peers, and whether muscle mea-
sures might explain any diﬀerences seen in size-adjusted bone density.
2. Methods
A cross-sectional study was conducted between July 2016 and July
2017 at the paediatric HIV clinic at Harare Central Hospital, Zimbabwe.
This is a public sector clinic that provides HIV care for> 1500 children.
Children were eligible for the study if they were aged between 6 and
16 years, had been taking ART for at least 6 months, were not acutely
unwell (no acute symptoms) and were not taking treatment for tu-
berculosis. Up to ﬁve eligible participants were consecutively recruited
per day, restricted to this number due to logistical constraints. Children
were convenience sampled within logistical and budgetary constraints.
A comparison group of HIV-uninfected children in the same age group
was recruited from seven primary care clinics that provided opt-out HIV
testing and counselling to all attendees regardless of the reason for
attendance, and that served the same catchment population as that of
Harare Central Hospital. Children who tested HIV negative, were not
acutely unwell and were not receiving treatment for tuberculosis were
enrolled.
2.1. Data collection
A nurse-administered questionnaire was used to collect socio-de-
mographic data, clinical history including age at HIV diagnosis and ART
initiation, ART regimen, history of menarche and voice breaking.
Where possible, clinical history was conﬁrmed with documentation
within patient hand-held medical records. A standardized examination
was performed including WHO staging of HIV infection and measure-
ment of height and weight using SECA® height board and electronic
SECA® weighing scales (Seca United Kingdom, Birmingham, England)
and Tanner pubertal stage using standardized protocols and calibrated
equipment. Hand grip strength in kilograms was measured using a
Jamar hydraulic hand-held dynamometer (Patterson Medical, UK).
Participants were seated with the shoulder at 0° to 10°, the elbow at 90°
of ﬂexion and the forearm positioned neutrally [17]. Three measure-
ments were taken from each hand in alternation by trained staﬀ, and
the highest measurement from the six taken was used in analyses. Age
and CD4 count at diagnosis were collected from hand held medical
records and based on guardian report if no record was available.
2.2. Dual-energy X-ray absorptiometry measurements
Dual X-ray absorptiometry (DXA) scans were performed by two
trained radiographers using standard procedures on a Hologic QDR Wi
densitometer (Hologic Inc., Bedford, MA, USA) with Apex Version 4.5
software for scan analysis. Daily calibration was conducted using a
manufacturer provided spine phantom. Lumbar spine (LS) and Total
body (TB) scans were performed from which BMC (Bone Mineral
Content), and TB fat mass were measured, TB lean mass calculated as
fat-free mass, and areal BMD (Bone Mineral Density) calculated (re-
peated phantom measures generated coeﬃcients of variation< 0.5%).
DXA calculates two-dimensional (areal) BMD which is highly depen-
dent upon bone size [18–20] and is therefore unsuitable for use in
growing children; DXA underestimates BMD when bones are small
[21]. Therefore, size adjustment techniques, as recommended by the
International Society for Clinical Densitometry (ISCD) [22], were used
to measure bone mineral apparent density (BMAD) Z-score at the
lumbar spine and regression-based total-body less-head (TBLH) Bone
Mineral Content (BMC) for lean mass adjusted for height (TBLH-
BMCLBM) Z-score, using, in the absence of African reference datasets,
the recommended age and gender speciﬁc reference data derived from
growth curves for white children in the UK (the ALPHABET dataset:
Amalgamated Reference Data for Size-Adjusted Bone Densitometry
Measurements in Children and Young Adults) [23]. TBLH-BMC, which
is considered one of the most accurate and reproducible methods in
children, was measured [22]. Then Z-scores for TBLH-BMC adjusted for
Lean Body Mass, fat mass and height (BMCLBM) were generated from
ALPHABET regression-derived reference growth curves [23]. The head
is excluded as it represents a greater proportion of skeletal mass in
younger children and may obscure important skeletal deﬁcits. Fur-
thermore, the head is not weight-bearing and does not grow in response
to factors like physical activity [22]. Low LS-BMAD and low TBLH-
BMCLBM were both deﬁned as a Z-score≤−2, according to re-
commended clinical deﬁnitions [22].
2.3. Laboratory investigations
Among CWH, HIV viral load was measured using COBAS
Ampliprep/Taqman 48 Version 2.0 (Roche, Rotkreuz, Switzerland) and
CD4 cell count was measured using an Alere PIMA CD4 (Waltham,
Massachusetts, USA) machine.
2.4. Ethical approval
Ethical approval was granted by the Medical Research Council of
Zimbabwe (MRCZ/A/1856), the Harare Hospital Ethics Committee, the
Biomedical Research and Training Institute Institutional Review Board
(AP125) and the London School of Hygiene and Tropical Medicine
Ethics Committee (8263). All guardians gave written consent, and
participants gave written assent to participate in the study.
2.5. Data analysis
Data were extracted from paper forms using optical character re-
cognition software (Cardiﬀ TELEFORM Intelligent Character, Version
10.7; Hewlett Packard, Palo Alto, California, USA). Data analysis was
carried out using Stata v13 (StataCorp, College Station, Texas, USA).
Height-for-age and body mass-for-age Z-scores were calculated using
the WHO reference standards [24].
Continuous variables were summarised as mean (standard devia-
tion: SD) and median (inter-quartile range: IQR), and categorical vari-
ables as counts (percentages). Multivariable linear regression models
were used to examine the diﬀerences in bone and muscle measures
between participants with and without HIV infection. Continuous out-
come variables were standardized for regression analyses, so that dif-
ferences are presented, with 95% conﬁdence intervals (95% CI), as the
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number of SDs diﬀerence between HIV infected and uninfected parti-
cipants. Serial adjustments to diﬀerences in bone and muscle measures
were decided a priori; model 1: adjusted for age and sex, model 2: ad-
justed for age, sex, height (categorised by 10 cm increments to account
for any non-linearity), model 4: adjusted for age, sex, height, and
puberty. As Hologic derived TBLH-BMCLBM takes account of lean mass
and height, these were not adjusted for further in TBLH-BMCLBM
models. Modiﬁcation of the eﬀect of age at ART initiation by tenofovir
use on bone outcomes, of lean mass and muscle function by HIV status
on bone outcomes, and of age at the time of DXA by HIV status on bone
and muscle outcomes, were investigated by ﬁtting appropriate inter-
action terms to linear regression models. In addition, we calculated
correlation coeﬃcients for ﬁgures comparing two linear variables.
3. Results
A total of 97 CWH and 77 uninfected participants were recruited, of
whom 52% were female. Participants with HIV were older than those
uninfected, mean (SD) 12.7 (2.5) vs. 10.0 (2.9) years, and hence were
taller and heavier (Table 1). A high proportion of CWH were stunted
compared to those uninfected (32% vs. 5%, p < 0.001). All CWH were
infected perinatally, and 22% of HIV-uninfected individuals reported
having a mother with HIV.
The 97 CWH had a median age at diagnosis of 4 years (IQR 2–7)
(Table 2). The median age at initiation of ART was 5.9 years (IQR
3.2–8.4) and 44 (46%) reported past or current tenofovir use. At en-
rolment, 79% were virologically supressed (HIV viral load<400 co-
pies/ml) and the median CD4 count was 733 (IQR 473–983) cells/mm3.
Only one child with HIV reported a prior history of an arm fracture.
3.1. Bone density
Low LS-BMAD (i.e. a Z-score≤−2) was more common among CWH
than those uninfected, 15% vs. 1% (p=0.002); the same was true for
low TBLH-BMCLBM found in 13% vs. 3%, p=0.018 (Table 1). Among
CWH, there was no association between stunting, deﬁned as a height-
for-age (HFA) Z-score < −2, and of low BMAD at the lumbar spine (p
value= 0.36) or of low TBLH-BMCLBM (p value= 0.81).
Initially, in unadjusted analyses, CWH appeared to have higher
lumbar spine BMC than uninfected individuals (Table 1), but when
comparing BMAD, which takes account of body size, this diﬀerence was
no longer observed (Table 1). However, when then comparing BMAD Z-
scores, which standardises for age and gender, the LS-BMAD Z-scores
were signiﬁcantly lower in CWH compared to uninfected children
(mean −0.742 vs. −0.093, p < 0.001) (Table 1). Similar patterns
were seen in the TBLH after taking account of body size and after
standardisation for age and gender, with a mean TBLH-BMCLBM Z-score
of −0.643 in CWH compared to Z-score −0.314 in those uninfected,
p=0.045. After adjustment for age, sex, height and puberty, a diﬀer-
ence was still seen in LS-BMAD between CWH and uninfected children,
such that the mean diﬀerence was 0.33 SDs (95% CI -0.01, 0.67;
p=0.055) lower in CWH compared to those without HIV, whilst no
clear diﬀerence in TBLH-BMCLBM [0.26 SDs (95% CI -0.09, 0.61;
p=0.148)] was observed between CWH and those without HIV.
In CWH, there was a concerning inverse association between age
and LS-BMAD Z-Score, and to a lesser extent TBLH-BMCLBM Z-Score
(Fig. 1, unadjusted). This contrasted with the stable LS-BMAD and
TBLH-BMCLBM Z-Scores seen across all ages among children without
HIV. This suggests that older CWH are more likely to have a low LS-
BMAD in comparison with their peers without HIV. In support of this,
there was modiﬁcation of the eﬀect of age on LS-BMAD Z-score by HIV
status (interaction p=0.03).
Table 1
Characteristics of study participants by HIV status.
Children with
HIV (n= 97)
Uninfected
children (n= 77)
p value
General characteristics
Mean (SD)
Age at DXA scan, years 12.7 (2.5) 10.0 (2.9) < 0.001
Height, cm 141.5 (11.4) 134.0 (16.6) < 0.001
Weight, kg 35.2 (9.5) 31.1 (10.5) 0.007
BMI, kg/m2 17.3 (2.6) 16.8 (1.9) 0.175
N (%)
Gender, female 51 (52.6) 40 (52.0) 0.934
Puberty (menarche or voice
broken)a
25 (26.0)b 11 (14.3) 0.058
Mother known to be HIV
infected
97 (100) 17 (22.1) < 0.001
Stunted (HFA
Z-score≤−2)
31 (32.0) 4 (5.2) < 0.001
Underweight (BFA
Z-score≤−2)
14 (14.4) 0 (0.0) 0.001
DXA and grip strength characteristics
Mean (SD)
Maximal handgrip
strength, kg
21.0 (8.2)c 16.2 (6.5)d < 0.001
TB Lean mass, kg 26.2 (6.3)e 23.0 (7.8) 0.003
TB Fat mass, kg 9.1 (4.6)e 8.6 (3.7) 0.397
TBLH-BMC, g 896.0 (262.7)e 789.0 (333.4) 0.019
TBLH-BMCLBM Z-score −0.643 (1.189) −0.314 (0.882) 0.045
L spine BMC, g 28.4 (8.9) 24.9 (11.4) 0.023
L spine BMAD, g/cm2 0.196 (0.037) 0.195 (0.032) 0.801
L spine BMAD Z-score −0.742
(1.295)e
−0.093 (0.886) < 0.001
N (%)
Low TBLH-BMCLBM
(Z-score≤−2)
12 (12.5)e 2 (2.6) 0.018
Low L Spine BMAD
(Z-score≤−2)
14 (14.6)e 1 (1.3) 0.002
BMI, Body Mass Index; HFA, Height for Age; BFA, Body Mass for Age; SD,
Standard Deviation; DXA, Dual energy X-ray Absorptiometry; TB, Total Body;
TBLH, Total-Body Less Head; BMC, Bone Mineral Content; TBLH-BMCLBM; total-
body less-head Bone Mineral Content for lean mass adjusted for height; BMAD,
Bone Mineral Apparent Density; L spine, Lumbar Spine.
Students t-test for continuous data and χ2 test for categorical data (i.e. un-
adjusted).
a Mean age at puberty 11.9 (2.6) years for CWH and 9.5 (2.9) years for
children without HIV. 16 girls with HIV had reached menarche at mean [SD]
age 13.5 [2.5] years, compared with 7 girls without HIV 13.2 [1.4] years.
b n= 96 CWH with data.
c n=85.
d n= 71.
e n= 96.
Table 2
HIV-speciﬁc summary characteristics among the 97 children with HIV.
Mean (SD) Median (IQR)
Age at HIV diagnosis, years 4.7 (3.0) 4 (2–7)
Time since HIV diagnosisa, years 8.1 (2.5) 8.1 (6.8–9.2)
Age at ART initiation, years 6.2 (3.4) 5.9 (3.2–8.4)
CD4 count at time of HIV diagnosis, cells/mm3b 459.9 (333.7) 386 (242–696)
CD4 count at study recruitment, cells/mm3 764.0 (372.8) 733 (473–983)
N (%)
Viral load suppressed <400 copies/ml 77 (79.4)
ART regime ever included Tenofovirc 44 (45.8)
DXA; Dual energy X-ray Absorptiometry, ART; Antiretroviral Therapy, SD;
Standard Deviation; IQR, Inter-quartile Range.
a At time of DXA scan.
b n=47.
c n= 96.
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3.2. Bone density and HIV treatment
Age at ART initiation was associated with both TBLH-BMCLBM Z-
score and LS-BMAD Z-score, such that for each year ART initiation was
delayed, there was a 0.08 SD reduction in TBLH-BMCLBM and 0.13 re-
duction in LS-BMAD (Fig. 2). This means that those children starting
ART after the age of 8 years had on average, at least a 1 SD reduction in
LS-BMAD compared with the reference population. There was no
modiﬁcation of this eﬀect by the use of tenofovir as part of the ART
regimen (p=0.37), but numbers were small (Supplementary Fig. 1).
Those who took tenofovir had a signiﬁcantly lower LS-BMAD Z-scores
than those who had not received tenofovir (mean [SD]−1.14 [1.28] vs.
−0.44 [1.23], p=0.008); a less marked diﬀerence was seen for TBLH-
BMCLBM Z-Score (−0.90 [1.02], vs. −0.46 [1.28], p=0.072).
Fig. 1. Unadjusted relationships between age and TBLH-BMCLBM and LS BMAD Z-scores, lean muscle mass, grip strength, stratiﬁed by HIV status. Red unbroken line
and squares indicate children with HIV (CWH). Blue dotted line and triangles indicate children without HIV infection. DXA, Dual energy X-ray Absorptiometry;
TBLH-BMCLBM; total-body less-head Bone Mineral Content for lean mass adjusted for height; BMAD, Bone Mineral Apparent Density. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Unadjusted relationships between age at ART initiation and TBLH-BMCLBM and Lumbar spine BMAD Z-scores among children with HIV. ART; Antiretroviral
Therapy; TBLH-BMCLBM; total-body less-head Bone Mineral Content for lean mass adjusted for height; BMAD, Bone Mineral Apparent Density.
C.L. Gregson, et al. Bone 125 (2019) 96–102
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3.3. Muscle mass & function
Age was positively associated with lean mass and with muscle
function (grip strength), in both CWH and children without HIV, al-
though uninfected children demonstrated a stronger association be-
tween age and lean mass, than did CWH (interaction p=0.008)
(Fig. 1). The greater body weight measured among CWH, compared to
those children without HIV, was explained by a higher relative pro-
portion of lean mass, rather than increased fat mass (Table 1). Corre-
spondingly, muscle function, measured as maximal grip strength, was
found to be greater among CWH than those uninfected; however, after
adjusting for age and sex, no diﬀerence in muscle function was ob-
served (Table 3). After similar adjustment, CWH had a lower lean mass
than those who were uninfected, but this was explained by diﬀerences
in height and pubertal stage between the two groups (Table 3). No clear
relationships were seen between either lean mass or muscle function
and TBLH-BMCLBM or LS-BMAD Z-scores, in participants with or
without HIV (Supplementary Fig. 2).
4. Discussion
Our study showed that low size-adjusted bone density is common
among CWH, the majority of whom were pre-pubertal. This low bone
density was observed in both trabecular-rich skeletal sites (i.e. 15%
having low lumbar spine BMAD) and cortical-rich sites (i.e. 13% having
low TBLH-BMCLBM). Importantly, the age at ART initiation was a key
predictor of lumbar spine bone density, such that children starting ART
after the age of 8 years had on average, at least a 1 SD reduction in
lumbar spine BMAD compared with the reference population. This is a
clinically important eﬀect size, as it is thought that a 1 SD reduction in
bone density doubles both childhood and, if sustained, future adult
fracture risk [7,25]. Given the recent report that current median age of
ART initiation in Sub-Saharan Africa is 7.9 years [26], the extrapolation
that potentially half of such children may be at signiﬁcant increased
fracture risk is of concern. There was also evidence of lower bone
density, particularly in trabecular-rich skeletal sites, in those children
treated with tenofovir as part of their ART regimen. In Zimbabwe te-
nofovir forms part of the ﬁrst-line ART regimen in children aged
12 years or older and/or who weigh 35kgs or more. Hence, our ﬁndings
from a relatively young population, with a relatively short duration of
tenofovir exposure, may underestimate any eﬀect of tenofovir on the
growing skeleton. These ﬁndings are consistent with several studies in
adults [27]; however, data from children have been less consistent [28]
and longitudinal data in larger populations, including those in Sub-
Saharan Africa, are needed to determine whether this association is
transient or persists after treatment initiation.
Our ﬁndings show that stunting is not a proxy for low size-adjusted
bone density. Adolescent skeletal growth is not linearly and structurally
uniform; peak height velocity precedes peak bone content accrual [29],
yet how bone is accrued in the context of HIV infection with associated
delayed puberty, and hence skeletal maturation [30], is poorly under-
stood. Despite CWH being on average 2.7 years older than those unin-
fected, only 14% more CWH had entered puberty. HIV infection is an
established cause of pubertal delay and it is possible that some of the
eﬀect of HIV infection on size-adjusted bone density may be mediated
through this mechanism [31,32].
After accounting for body size and pubertal stage, no diﬀerences
were seen in muscle mass or function between those with and without
HIV infection. Furthermore, neither muscle mass nor function was as-
sociated with bone density, suggesting that muscle is not aﬀected in the
same way as bone in the context of longstanding paediatric HIV in-
fection. A small study of 15 Puerto Rican CWH also found CWH to have
similar lower limb muscle strength to uninfected controls [33]. Al-
though, a more recent Canadian study which assessed lower limb
muscle function by jumping mechanography, in a population 2 years
older than ours (n=35), did ﬁnd an albeit small diﬀerence in lower
limb muscle power [13]. Whether power rather than strength, or lower
limb rather than upper limb function, may be aﬀected by HIV infection
remains to be determined.
The Children with HIV Early Antiretroviral Therapy (CHER) trial
showed substantially reduced mortality in infants with immediate ART
initiation, leading to recommendations that all infants with HIV should
be treated with ART following diagnosis [34]. There has been no such
beneﬁt demonstrated in older children [35,36] and until recently,
guidelines for treatment eligibility for older children and adolescents
were the same as those for adults, based on disease or immunological
stage [37,38]. The recent START and TEMPRANO trials both demon-
strated that early initiation of ART reduced the risk of severe illnesses
[39,40]; these trials were conducted in adults only and excluded older
children and adolescents. Our ﬁndings add strong support to the recent
WHO treatment guidelines which recommend prompt ART initiation
following diagnosis of HIV infection regardless of clinical or im-
munological stage of infection in children [38]. While these guidelines
are a positive step towards improvement of health of CWH, there likely
remains a cohort of children in Sub-Saharan Africa who are missed by
programmes to prevent mother-to-child transmission, including early
infant diagnosis, and who will therefore be diagnosed in later childhood
[41]. Furthermore, children progressing through adolescence are at
high risk of poor adherence and therefore inadequate viral suppression,
which may put their bone health at risk [42]. It remains to be seen
whether improved ART roll-out will ameliorate this risk, or whether
there will be a higher than expected fracture burden in the region in the
future.
Our study highlights the importance of using the ‘gold-standard’
size-adjustment methodology when conducting studies of bone density
in the growing skeleton, particularly in the context of HIV where
stunting is so common. Other strengths of this study are the prospective
and (based on symptoms) unselected recruitment of participants. Until
now, DXA-based studies in CWH in Sub-Saharan Africa have been
limited to South Africa [43]. DXA capacity is severely limited across the
region [44], so that such studies are logistically challenging. Our study
has limitations, including the cross-sectional nature of the study design
which prevents causal inference, and the older age of the infected
compared to uninfected participants which explain the height and
weight diﬀerences seen, although our analyses enabled suitable ad-
justment. We lacked hand/wrist radiographs from which to derive bone
Table 3
Diﬀerences in Lumbar Spine BMAD, TBLH-BMCLBM, muscle mass and muscle
function between children with and without HIV infection, after serial adjust-
ments.
N Mean diﬀerence (95% CI) p value
TBLH-BMCLBM
Model 1: age, sex 172 −0.30 (−0.64, 0.04) 0.088
Model 3*: age, sex, puberty 172 −0.26 (−0.61, 0.09) 0.148
Lumbar spine BMAD
Model 1: age, sex 172 −0.41 (−0.73, −0.09) 0.011
Model 2: age, sex, height 172 −0.39 (−0.71, −0.06) 0.022
Model 3: age, sex, height, puberty 172 −0.33 (−0.67, 0.01) 0.055
Lean muscle mass
Model 1: age, sex 172 −0.38 (−0.56, −0.20) < 0.001
Model 2: age, sex, height 172 −0.16 (−0.29, −0.03) 0.019
Model 3: age, sex, height, puberty 172 −0.11 (−0.24, 0.03) 0.111
Muscle grip strength
Model 1: age, sex 154 −0.10 (−0.31, 0.11) 0.353
Model 2: age, sex, height 154 −0.01 (−0.22, 0.20) 0.924
Model 3: age, sex, height, puberty 154 0.05 (−0.16, 0.27) 0.620
BMAD; Bone Mineral Apparent density, TBLH-BMCLBM; total-body less-head
Bone Mineral Content for lean mass adjusted for height. CI; Conﬁdence interval.
Model 1: adjusted for age and gender. Model 2: model 1 & height (as category).
Model 3: model 2 & puberty. Model 3*: adjusted for age, gender and puberty.
Mean diﬀerences are shown in SD units, negative Betas (mean diﬀerence va-
lues) indicate a lower measured outcome in the group with HIV infection.
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age as a more accurate measure of skeletal maturation than chron-
ological age adjusted for Tanner stage. We lacked data to permit ana-
lysis of diﬀering ART regimes and durations and their associations with
weight, height and bone measurements. Notably, 22% of our uninfected
children reported maternal HIV infection, hence these children may
have been exposed but uninfected. It is unclear whether such children
are at risk of impaired skeletal development, if so, this may have led us
to underestimate the true magnitude of diﬀerence between CWH and
uninfected (and unexposed) children. Furthermore, there is a global
lack of bone density reference data for child/adolescent populations in
Africa, which meant that following International Society for Clinical
Densitometry (ISCD) guidance [22], we used the recommended age and
gender speciﬁc reference data derived from white children in the UK
[23]. Future studies are needed to establish normative data for African
populations.
In conclusion, perinatally-acquired HIV infection is associated with
both stunting and low lumbar spine bone density (adjusted for size) in
Zimbabwean children, but importantly these conditions appear to be
independent of one another. Such low bone density has been associated
with substantially increased fracture risk in other populations. Our
ﬁndings suggest delays in initiating ART contribute to lower bone
density in CWH, and our ﬁndings support the current recommendations
to initiate ART regardless of disease or immunological stage.
Longitudinal data are needed from high HIV prevalence settings in Sub-
Saharan Africa to establish how size-adjusted bone density changes
through pubertal growth and following treatment of HIV infection,
together with future fracture incidence studies.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bone.2019.05.012.
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